Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH + Ofatumumab/Rituximab in Burkitt Lymphoma or ALL
NCT02199184Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2015
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in Burkitt lymphoma (BL), acute lymphoblastic leukemia (ALL), high grade B-cell lymphoma (HGBCL), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2015; status: completed.
02
Drugs
ofatumumab
03
Conditions
Burkitt lymphoma (BL)acute lymphoblastic leukemia (ALL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT02199184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199184.